poisar

Stocks · News reference

European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication

Vandana Singh

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGNSNY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Prosper Junior Bakiny

    Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

    The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.

    VRTXREGN
  3. Andy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    AMGNVRTXREGN
  5. Na

    Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

    Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.

    MRNAGSKMRKSNY
  6. Na

    Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

    Eli Lilly announced a definitive agreement to acquire clinical-stage biotech Merida Biosciences for up to $2.875 billion in an all-cash transaction. The deal adds MER511 for Graves' disease and thyroid eye disease, along with preclinical candidates for allergy and kidney disease. This acquisition marks Lilly's 10th major deal in 2026 as the company diversifies its pipeline beyond cardiometabolic medicines, leveraging strong cash generation from its blockbuster GLP-1 drugs.

    LLYBMYCELGRSNY